• In the past quarter, Azenta, Inc. reported third-quarter 2026 revenue of US$161.18 million and net income of US$2.46 million, a swing from a net loss a year earlier, while also completing a US$50 million repurchase of 2,300,000 shares.
• Azenta also raised its full-year revenue guidance to a range of US$613 million to US$618 million, signaling greater confidence in its ongoing operations and cash generation after returning to quarterly profitability.
• We’ll now look at how Azenta’s return to quarterly profitability and higher full-year revenue guidance affect its broader investment narrative.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free.

Azenta Investment Narrative Recap

To own Azenta, I think you need to believe its sample management and multiomics services can convert steady life sciences demand into durable profitability, despite recent years of losses and industry budget pressures. The return to quarterly profitability and higher full-year revenue guidance support that case in the near term, but the biggest risk remains that ongoing softness in certain sequencing and synthesis lines, combined with elevated R&D and infrastructure spend, could still hold back margins and free cash flow. Overall, this quarter’s news looks helpful but not transformational to that risk-reward balance.

Among the recent company updates, the completion of the US$50 million repurchase of 2,300,000 shares stands out alongside the earnings release, as it meaningfully reduced the share count while Azenta reported positive quarterly net income of US$2.46 million on revenue of US$161.18 million. For investors focused on short term catalysts, this pairing of buybacks with a return to profitability may sharpen attention on how consistently Azenta can sustain positive earnings from here.

Yet even with these improvements, investors should be aware that ongoing pressure on high margin instruments and services could still...

Azenta's narrative projects $685.0 million revenue and $37.8 million earnings by 2029. This requires 4.7% yearly revenue growth and a $148.7 million earnings increase from -$110.9 million today.

Uncover how Azenta's forecasts yield a $27.80 fair value, a 17% downside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were assuming Azenta would reach only about US$678.7 million in revenue and US$33.5 million in earnings by 2029, so this quarter’s profitability and guidance raise could challenge that more pessimistic view of margin pressure and slow improvement, and it is worth weighing how your own expectations compare before deciding which narrative you find more convincing.

Explore 2 other fair value estimates on Azenta - why the stock might be worth as much as $27.80!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Azenta research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Azenta research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Azenta's overall financial health at a glance.

Want Some Alternatives?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Find 51 companies with promising cash flow potential yet trading below their fair value.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.